Dr. Dinesh Khanna, MD, MSc, Professor of Rheumatology and Medicine at the University of Michigan and coordinating investigator on this trial discusses the Phase 2b pivotal trial to evaluate Horizon Therapeutics’ HZN-825 to treat people with diffuse cutaneous systemic sclerosis (dcSSc).
Dr. Dinesh Khanna is a rheumatology specialist at the University of Michigan. He directs a multidisciplinary group of caregivers, scientists, and clinical researchers dedicated to advancing knowledge about scleroderma and related conditions. His research interests include developing new patient-reported outcome measures in patients with scleroderma and different diseases of the joint, and clinical trial design in evaluating new treatments for scleroderma. In addition, he is leading international efforts to develop guidelines for the management of scleroderma and gout.